1Table 1: BRIC generics industry, revenue($bn), 2012-21
2Table 2: BRIC generics industry, revenue($bn), 2012-16
3Table 3: BRIC generics industry, revenue($bn), 2016-21
4Table 4: Brazil generics market value: $ billion, 2012–16
5Table 5: Brazil generics market volume: % of total pharma volume, 2012–16
6Table 6: Brazil generics market geography segmentation: $ billion,2016
7Table 7: Brazil generics market value forecast: $ billion, 2016–21
8Table 8: Brazil generics market volume forecast: % of total pharma volume, 2016–21
9Table 9: Brazil size of population (million), 2012–16
10Table 10: Brazil gdp (constant 2005 prices, $ billion), 2012–16
11Table 11: Brazil gdp (current prices, $ billion), 2012–16
12Table 12: Brazil inflation, 2012–16
13Table 13: Brazil consumer price index (absolute), 2012–16
14Table 14: Brazil exchange rate, 2012–16
15Table 15: China generics market value: $ billion, 2012–16
16Table 16: China generics market volume: % of total pharma volume, 2012–16
17Table 17: China generics market geography segmentation: $ billion,2016
18Table 18: China generics market value forecast: $ billion, 2016–21
19Table 19: China generics market volume forecast: % of total pharma volume, 2016–21
20Table 20: China size of population (million), 2012–16
21Table 21: China gdp (constant 2005 prices, $ billion), 2012–16
22Table 22: China gdp (current prices, $ billion), 2012–16
23Table 23: China inflation, 2012–16
24Table 24: China consumer price index (absolute), 2012–16
25Table 25: China exchange rate, 2012–16
26Table 26: India generics market value: $ billion, 2012–16
27Table 27: India generics market volume: % of total pharma volume, 2012–16
28Table 28: India generics market geography segmentation: $ billion,2016
29Table 29: India generics market value forecast: $ billion, 2016–21
30Table 30: India generics market volume forecast: % of total pharma volume, 2016–21
31Table 31: India size of population (million), 2012–16
32Table 32: India gdp (constant 2005 prices, $ billion), 2012–16
33Table 33: India gdp (current prices, $ billion), 2012–16
34Table 34: India inflation, 2012–16
35Table 35: India consumer price index (absolute), 2012–16
36Table 36: India exchange rate, 2012–16
37Table 37: Russia generics market value: $ billion, 2012–16
38Table 38: Russia generics market volume: % of total pharma volume, 2012–16
39Table 39: Russia generics market geography segmentation: $ billion,2016
40Table 40: Russia generics market value forecast: $ billion, 2016–21
41Table 41: Russia generics market volume forecast: % of total pharma volume, 2016–21
42Table 42: Russia size of population (million), 2012–16
43Table 43: Russia gdp (constant 2005 prices, $ billion), 2012–16
44Table 44: Russia gdp (current prices, $ billion), 2012–16
45Table 45: Russia inflation, 2012–16
46Table 46: Russia consumer price index (absolute), 2012–16
47Table 47: Russia exchange rate, 2012–16
48Table 48: O Ache Laboratorios Farmaceuticos S.A.: key facts
49Table 49: EMS Sigma Pharma: key facts
50Table 50: Eurofarma Laboratórios S.A.: key facts
51Table 51: Sanofi SA: key facts
52Table 52: Sanofi SA: key financials ($)
53Table 53: Sanofi SA: key financials (€)
54Table 54: Sanofi SA: key financial ratios
55Table 55: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts
56Table 56: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)
57Table 57: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)
58Table 58: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios
59Table 59: Mylan Inc.: key facts
60Table 60: Mylan Inc.: key financials ($)
61Table 61: Mylan Inc.: key financial ratios
62Table 62: Sandoz International GmbH: key facts
63Table 63: Aurobindo Pharma Limited: key facts
64Table 64: Aurobindo Pharma Limited: key financials ($)
65Table 65: Aurobindo Pharma Limited: key financials (Rs.)
66Table 66: Aurobindo Pharma Limited: key financial ratios
67Table 67: Cipla Limited: key facts
68Table 68: Cipla Limited: key financials ($)
69Table 69: Cipla Limited: key financials (Rs.)
70Table 70: Cipla Limited: key financial ratios
71Table 71: Lupin Limited: key facts
72Table 72: Lupin Limited: key financials ($)
73Table 73: Lupin Limited: key financials (Rs.)
74Table 74: Lupin Limited: key financial ratios
75Table 75: Sun Pharmaceutical Industries Ltd.: key facts
76Table 76: Sun Pharmaceutical Industries Ltd.: key financials ($)
77Table 77: Sun Pharmaceutical Industries Ltd.: key financials (Rs.)
78Table 78: Sun Pharmaceutical Industries Ltd.: key financial ratios
79Table 79: Abbott Laboratories: key facts
80Table 80: Abbott Laboratories: key financials ($)
81Table 81: Abbott Laboratories: key financial ratios
82Table 82: Krka, d. d., Novo mesto: key facts
83Table 83: Krka, d. d., Novo mesto: key financials ($)
84Table 84: Krka, d. d., Novo mesto: key financials (€)
85Table 85: Krka, d. d., Novo mesto: key financial ratios
86Table 86: Teva Pharmaceutical Industries Limited: key facts
87Table 87: Teva Pharmaceutical Industries Limited: key financials ($)
88Table 88: Teva Pharmaceutical Industries Limited: key financial ratios